Xarelto Approval For DVT Bodes Well For Coming Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's July 1 approval of Johnson & Johnson's oral anticoagulant comes after a long review process, and in front of some key decision points that will shape the rivaroxaban program's future.